SCHEMBL312426

SCHEMBL312426

OCC#Cc1c[nH]c2ncnc(Cl)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.49
MAP3K7 O43318 2/20 0.39
TAB1 Q15750 2/20 0.39
CHUK O15111 4/20 0.37
NOTUM Q6P988 1/20 0.36
LRRK2 Q5S007 6/20 0.35
PGK1 P00558 1/20 0.33
STK3 Q13188 6/20 0.32
STK4 Q13043 3/20 0.32
ROCK2 O75116 3/20 0.32
PRKD3 O94806 3/20 0.32
MAP4K4 O95819 3/20 0.32
CDK1 P06493 3/20 0.32
FGFR1 P11362 3/20 0.32
PHKG2 P15735 3/20 0.32
PRKACA P17612 3/20 0.32
RPS6KB1 P23443 3/20 0.32
CDK2 P24941 3/20 0.32
MARK3 P27448 3/20 0.32
FLT4 P35916 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310980 0.79 CHEK1 (0.43) CHEK1MAP3K7TAB1CHUKNOTUM
SCHEMBL1737697 0.79 CHEK1 (0.56) CHEK1MAP3K7TAB1CHUKNOTUM
SCHEMBL1735020 0.77 CHEK1 (0.50) CHEK1MAP3K7TAB1CHUKNOTUM
SCHEMBL311539 0.77 CHEK1 (0.46) CHEK1MAP3K7TAB1CHUKNOTUM
SCHEMBL154683 0.76 CHUK (0.61) CHEK1MAP3K7TAB1CHUKLRRK2
SCHEMBL5522262 0.75 CHEK1 (0.47) CHEK1CHUKLRRK2PRKD3MAP4K4
SCHEMBL3236479 0.72 CHEK1 (0.56) CHEK1MAP3K7TAB1CHUKNOTUM
SCHEMBL16254776 0.72 PGK1 (0.42) CHEK1CHUKLRRK2PGK1STK3
SCHEMBL312134 0.71 CHEK1 (0.43) CHEK1MAP3K7TAB1CHUKLRRK2
SCHEMBL5019486 0.70 CHEK1 (0.61) CHEK1MAP3K7TAB1CHUKNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2148880-B1 P70 S6 KINASE INHIBITORS LILLY CO ELI (US) 2014-05-28 EP disclosed
US-20120071490-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2012-03-22 US disclosed
US-8093383-B2 P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20090163714-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163714-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 CHEK1 521/4885MAP3K7 110/4885TAB1 1578/4885
US-20120071490-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 CHEK1 521/4885MAP3K7 110/4885TAB1 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.